急性髓系白血病诱导的人骨髓微环境重塑可预测临床结局
该研究在初诊急性髓系白血病(AML)患者中联合免疫组化与全基因表达分析解析骨髓微环境,发现间充质干/祖细胞(MSPC)失去静息状态并显著扩增,其成骨与骨形成能力受抑;外周血骨钙素水平较非白血病供者低30%,且骨钙素≤11 ng/mL者总生存更差。
要点
- 初诊AML患者骨髓MSPC失去静息并显著扩增,成骨与骨形成受抑。
- AML患者外周血骨钙素较非白血病供者低30%。
- 骨钙素≤11 ng/mL者1年生存率38.7%,高于此值者66.8%。
核心结论
- AML在初诊时即重塑人骨髓微环境,MSPC扩增但HSC与微环境调控能力受损。
- 外周血骨钙素水平较低的AML患者总生存更差。
研究设计与样本
- 在初诊AML患者中解剖骨髓微环境,联合免疫组化染色与全基因表达分析并关联临床特征。
主要发现
- MSPC失去静息状态并在AML患者骨髓中显著扩增。
- MSPC的HSC与微环境调控能力受损,成骨与骨形成显著受抑,呈细胞接触依赖方式并通过抑制胞质β-catenin实现。
- 初诊AML患者外周血骨钙素水平较非白血病供者低30%。
- 骨钙素≤11 ng/mL患者1年生存率38.7%,高于此水平患者为66.8%。
关键数值与推荐
- 外周血骨钙素≤11 ng/mL的初诊AML患者1年生存率38.7%,高于此水平者为66.8%。
- 初诊AML患者外周血骨钙素水平较非白血病供者低30%。
临床怎么用
- 初诊AML可评估外周血骨钙素水平以辅助预后分层。
- 骨钙素≤11 ng/mL提示总生存较差,需更密切随访。
- 骨髓微环境重塑分子(如β-catenin通路)可能成为AML微环境靶向治疗方向。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Murine models of myeloid neoplasia show how leukemia infiltration alters the hematopoietic stem cell (HSC) niche to reinforce malignancy at the expense of healthy hematopoiesis. However, little is known about the bone marrow architecture in humans and its impact on clinical outcome. Here, we dissect the bone marrow niche in patients with acute myeloid leukemia (AML) at first diagnosis. We combined immunohistochemical stainings with global gene expression analyses from these AML patients and correlated them with clinical features. Mesenchymal stem and progenitor cells (MSPCs) lost quiescence and significantly expanded in the bone marrow of AML patients. Strikingly, their HSC- and niche-regulating capacities were impaired with significant inhibition of osteogenesis and bone formation in a cell contact-dependent manner through inhibition of cytoplasmic β-catenin. Assessment of bone metabolism by quantifying peripheral blood osteocalcin levels revealed 30% lower expression in AML patients at first diagnosis than in non-leukemic donors. Furthermore, patients with osteocalcin levels ≤11 ng/mL showed inferior overall survival with a 1-year survival rate of 38.7% whereas patients with higher osteocalcin levels reached a survival rate of 66.8%. These novel insights into the human AML bone marrow microenvironment help translate findings from preclinical models and detect new targets which might pave the way for niche-targeted therapies in AML patients.
引用
- Chen Y, Hoffmeister LM, Zaun Y, et al. Acute myeloid leukemia-induced remodeling of the human bone marrow niche predicts clinical outcome. Blood Adv. 2020. PMID: 33108453. doi:10.1182/bloodadvances.2020001808
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。